BofA raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm’s higher target ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

该公司的分析表明，Alkermes的股价目前已经考虑了即期挑战，同时也计入了其开发中治疗药物的潜在收入。RBC Capital Markets的立场表明，他们正在密切关注更多数据，以进一步评估该药物在竞争市场中的前景以及公司的整体财务健康状况。 InvestingPro ...

RBC Capital initiated coverage of Alkermes (ALKS) with a Sector Perform rating and $40 price target The company’s next-generation orexin has a ...

2025年3月12日周三，Alkermes Plc（NASDAQ: ALKS）在2025年Leerink全球医疗大会上发表演讲，重点介绍了其Orexin管线和强劲商业产品的战略重点。公司在竞争压力下强调了其神经科学领域的重点和增长战略，同时阐述了机遇与挑战。

Modalert is widely recognized for its superb capability in enhancing cognitive power, concentration, and prolonged ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan planned ...

NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and ...

Orexin in the regulation of feeding and wakefulness[J]. Annual review of neuroscience, 2001, 24(1): 429-458. [4]Sakurai T. The role of orexin in motivated behaviours[J]. Nature Reviews Neuroscience, ...

The two major types of narcolepsy are: Narcolepsy type 1. People with type 1 narcolepsy have low levels of orexin (hypocretin), a brain chemical that regulates wakefulness. Damage to the brain ...